EMERALD: An assessment of feasibility of treating coronary microvascular dysfunction with SGLT2 inhibitors

Authors
Category Primary study
Registry of TrialsAustralian New Zealand Clinical Trials Registry
Year 2025
This article has no abstract
Epistemonikos ID: d5e73168859c45ee679904b85b1f1e21767e947a
First added on: Apr 26, 2025